Anika Therapeutics (ANIK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 30,602 | 29,559 | 30,724 | 29,022 | -2,899 |
| Cost of Goods | 13,476 | 10,151 | 10,235 | 10,047 | -8,672 |
| Gross Profit | 17,126 | 19,408 | 20,489 | 18,975 | 5,773 |
| Operating Expenses | 18,307 | 19,640 | 22,534 | 21,527 | -19,601 |
| Operating Income | -705 | -81 | -1,810 | -2,505 | 24,702 |
| Other Income | 744 | 406 | 595 | 592 | 577 |
| Pre-tax Income | 39 | 325 | -1,215 | -1,913 | 25,279 |
| Income Tax | 2,525 | 2,170 | 1,326 | 43 | 9,051 |
| Net Income Continuous | -2,486 | -1,845 | -2,541 | -1,956 | 16,228 |
| Net Income Discontinuous | -19,379 | -28,073 | 2,453 | -2,558 | N/A |
| Net Income | $-21,865 | $-29,918 | $-88 | $-4,514 | $-63,000 |
| EPS Basic Total Ops | -1.48 | -2.03 | -0.01 | -0.31 | -4.29 |
| EPS Basic Continuous Ops | -0.18 | -0.12 | -0.17 | -0.13 | 1.11 |
| EPS Basic Discontinuous Ops | -1.30 | -1.91 | 0.16 | -0.18 | N/A |
| EPS Diluted Total Ops | -1.48 | -2.03 | -0.01 | -0.31 | -4.29 |
| EPS Diluted Continuous Ops | -0.18 | -0.12 | -0.17 | -0.13 | 1.11 |
| EPS Diluted Discontinuous Ops | -1.31 | -1.91 | 0.17 | -0.18 | N/A |
| EPS Diluted Before Non-Recurring Items | -0.14 | -0.44 | 0.00 | N/A | N/A |
| EBITDA(a) | $468 | $5,208 | $248 | $-442 | $90,466 |